Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential staging in non-Hodgkin's lymphoma

B A Chabner, R E Johnson, V T DeVita

    Cancer Treatment Reports
    |September 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.

    Biochemical pharmacology·2010
    Same author

    Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

    Annals of oncology : official journal of the European Society for Medical Oncology·2007
    Same author

    Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.

    Annals of oncology : official journal of the European Society for Medical Oncology·2003
    Same author

    Primary treatment of Hodgkin's disease.

    Annals of oncology : official journal of the European Society for Medical Oncology·2002
    Same author

    Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease.

    Annals of oncology : official journal of the European Society for Medical Oncology·2002

    Staging non-Hodgkin's lymphoma (NHL) using lymphangiography, bone marrow, and liver biopsies revealed high rates of advanced disease in most subtypes. Histiocytic lymphoma showed a higher proportion of early-stage disease after comprehensive staging.

    Area of Science:

    • Oncology
    • Hematology
    • Diagnostic Imaging

    Background:

    • Accurate staging is crucial for non-Hodgkin's lymphoma (NHL) treatment planning.
    • Previous staging methods may not fully capture the extent of disease in all NHL subtypes.

    Purpose of the Study:

    • To evaluate the effectiveness of a comprehensive staging protocol for non-Hodgkin's lymphoma.
    • To determine the incidence of advanced disease across different NHL subtypes after staging.

    Main Methods:

    • Review of staging results in 170 patients with non-Hodgkin's lymphoma.
    • Sequential procedures included lymphangiography, bone marrow biopsy, and liver biopsy.
    • Biopsies were performed via percutaneous, peritoneoscopy, or laparotomy approaches.

    Related Experiment Videos

    Main Results:

    • High rates of bone marrow, liver, and abdominal node involvement were observed in nodular and diffuse lymphocytic lymphoma subtypes.
    • Only 20% of patients with these subtypes remained in Stage I or II post-staging.
    • Histiocytic lymphoma showed a higher percentage (31%) of patients in Stage I-II.
    • Laparotomy revealed liver or mesenteric/portal lymph node involvement in 81% of patients with positive lymphangiograms versus 18% with negative ones.

    Conclusions:

    • Comprehensive staging significantly downstages most non-Hodgkin's lymphoma subtypes, particularly nodular and diffuse lymphocytic types.
    • Histiocytic lymphoma presents a distinct pattern with a higher proportion of early-stage disease.
    • Lymphangiography is a valuable tool, with positive findings correlating strongly with intra-abdominal disease detected at laparotomy.